Eli Lilly and Company $LLY Stock Holdings Reduced by Cidel Asset Management Inc.

Key Points

• Cidel Asset Management reduced its Eli Lilly stake by 16.2% in the third quarter, selling 3,207 shares and retaining 16,647 shares valued at approximately $19.3 million. Institutional investors collectively own 82.53% of the company.
• Insiders have also been selling shares: company executives sold 13,500 shares worth about $16.0 million over the past 90 days, while corporate insiders own just 0.14% of the stock.
• Wall Street remains broadly bullish, with Eli Lilly receiving a “Moderate Buy” consensus rating and an average price target of $1,398.43. The company recently reported stronger-than-expected quarterly revenue and earnings, driven by Mounjaro and Zepbound sales, but faces valuation and pricing-pressure risks.

Cidel Asset Management Inc. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 16.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,647 shares of the company's stock after selling 3,207 shares during the quarter. Cidel Asset Management Inc.'s holdings in Eli Lilly and Company were worth $19,262,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Marshall & Sterling Wealth Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock worth $37,000 after buying an additional 15 shares during the period. Foresight Capital Management Advisors Inc. purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at about $49,000. AlphaCentric Advisors LLC purchased a new stake in Eli Lilly and Company during the 1st quarter valued at about $42,000. Caitlin John LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at about $64,000. Finally, IMG Wealth Management Inc. grew its position in Eli Lilly and Company by 500.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock worth $72,000 after acquiring an additional 50 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on LLY. Leerink Partners lifted their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 21st. Berenberg Bank raised Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 price objective for the company in a research note on Tuesday, September 15th. Scotiabank raised their target price on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a "sector outperform" rating in a report on Friday. HSBC lifted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research note on Thursday, September 10th. Finally, Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an "overweight" rating in a report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $1,398.43.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,415.64 on Monday. The business has a 50 day moving average of $1,197.72 and a 200 day moving average of $1,092.57. Eli Lilly and Company has a 52 week low of $834.19 and a 52 week high of $1,449.68. The company has a market cap of $1.33 trillion, a PE ratio of 45.95, a P/E/G ratio of 1.80 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. During the same quarter in the previous year, the business posted $7.02 earnings per share. The firm's revenue for the quarter was up 38.6% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company's dividend payout ratio is 22.46%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.